Article
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Clinical lung cancer - 1 Mar 2016
Boye Mark, Wang Xin, Srimuninnimit Vichien, Kang Jin Hyoung, Tsai Chun-Ming, Orlando Mauro, Puri Tarun, Kim Jong Seok, Rajan Narayan, Yang James Chih-Hsin
Abstract excerpt
BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.